Abstract IA006: Endocrine therapy and ER/PR combinations

Abstract

Endocrine therapy is the “original” targeted therapy in endometrial cancer (EC). Despite over 60 years experience with this treatment modality we have yet to answer some key questions including which women derive benefit and how do we identify them? Despite a high proportion of ECs being ER and/or PR positive, endocrine therapy is only associated with modest benefit. Greater understanding of ER and PR biology may help identify patient populations who will derive benefit and assist in optimizing this approach. Favourable toxicity profiles and multiple pathway interactions suggest the potential for combining endocrine and other targeted agents. We discuss the preliminary data and hypothesize on potential strategies to accelerate the pace of development in this area. Citation Format: Helen J. MacKay. Endocrine therapy and ER/PR combinations [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr IA006.